Secretory carcinoma of the salivary gland — recognized as a distinct entity in the WHO 2017 classification under the name mammary analogue secretory carcinoma (MASC) after its morphologic and molecular similarity to secretory carcinoma of the breast was established, now simply called secretory carcinoma in the WHO 2022 classification to reflect its recognition as a primary salivary gland entity independent of breast analogy — is a low-to-intermediate grade malignant salivary gland neoplasm arising most commonly in the parotid gland (approximately 50–60% of cases), followed by the minor salivary glands of the oral cavity (approximately 25–30%), and the submandibular gland and periparotid soft tissue, accounting for approximately 1–4% of all salivary gland tumors in contemporary series (likely underdiagnosed in earlier series where many cases were misclassified as acinic cell carcinoma before the molecular characterization of the ETV6::NTRK3 fusion), characterized histologically by microcystic, tubular, papillary-cystic, and solid growth patterns (often mixed within the same tumor) with cells showing abundant pale eosinophilic cytoplasm containing periodic acid-Schiff positive, diastase-resistant secretory vacuoles and intraluminal colloid-like secretory material — the "secretory" morphology that gives the tumor its name, defined at the molecular level by the ETV6::NTRK3 gene fusion — the same fusion present in secretory carcinoma of the breast and congenital fibrosarcoma — arising from the t(12;15)(p13;q25) translocation and detectable by FISH (break-apart ETV6 FISH or dual-fusion ETV6/NTRK3 FISH), RT-PCR, or comprehensive RNA sequencing, present in approximately 85–90% of secretory carcinomas, with the remaining 10–15% of cases demonstrating alternative NTRK3 fusion partners or ETV6 fusion partners, all of which converge on NTRK3 kinase activation — a molecular profile that makes secretory carcinoma the salivary gland tumor most directly actionable with TRK inhibitors (larotrectinib and entrectinib are FDA-approved for NTRK fusion-positive solid tumors and show high response rates in secretory carcinoma), classified by grade (low-grade: predominantly microcystic and tubular patterns with low mitotic rate and absent necrosis — the typical presentation; high-grade transformation: increased mitotic activity, comedonecrosis, solid sheet growth, nuclear pleomorphism — associated with aggressive behavior, lymph node metastasis, and distant metastasis; the proportion of cases with high-grade transformation is approximately 10–15%), with clinical behavior of low-grade secretory carcinoma being generally favorable (local recurrence in approximately 15–25% without adequate surgery; cervical lymph node metastasis in approximately 20–30% at presentation; 5-year disease-specific survival for low-grade cases exceeding 80–90%; high-grade transformation associated with substantially worse prognosis), treated with surgical resection (parotidectomy — total or partial/superficial depending on deep lobe involvement — with facial nerve monitoring and preservation as the goal for N0 low-grade disease; neck dissection for clinical nodal disease and high-grade transformation; selective or elective neck dissection considered for T2+ low-grade disease given the 20–30% nodal positivity rate), with adjuvant radiotherapy for adverse features (perineural invasion, close/positive margins, nodal disease, high-grade transformation), and with NTRK inhibitor therapy (larotrectinib, entrectinib) for recurrent or metastatic secretory carcinoma — making integrated head and neck surgical oncology, surgical pathology with ETV6::NTRK3 molecular confirmation, and NTRK inhibitor oncology platforms essential.
Secretory carcinoma technology platforms — whether supporting the surgical pathology programs performing secretory carcinoma diagnosis and ETV6::NTRK3 molecular confirmation (microcystic, tubular, and papillary-cystic growth pattern documentation; secretory vacuole and colloid-like intraluminal material identification; high-grade transformation features; ETV6 break-apart FISH or dual-fusion ETV6/NTRK3 FISH; acinic cell carcinoma exclusion — the principal differential diagnosis before molecular testing — by ETV6 FISH; IHC panel — S100 diffuse positive, mammaglobin diffuse positive, GATA3 positive, SOX10 positive, DOG1 and NR4A3 negative [acinic cell carcinoma exclusion], PAS-diastase positive secretory vacuoles), the imaging programs performing MRI parotid and CT neck for primary extent, deep lobe involvement, and regional nodal staging, the head and neck surgery programs performing parotidectomy (superficial or total with facial nerve monitoring and preservation; deep lobe resection for deep lobe involvement; neck dissection for nodal disease and high-grade transformation), the radiation oncology programs delivering adjuvant IMRT for adverse-feature disease, the medical oncology programs managing NTRK inhibitor therapy (larotrectinib, entrectinib) for recurrent or metastatic secretory carcinoma with ETV6::NTRK3 fusion confirmation, the molecular profiling platforms performing ETV6 FISH, NTRK3 rearrangement confirmation, comprehensive RNA fusion sequencing for alternative fusion partners, and NTRK IHC as a screening tool, and the multidisciplinary head and neck tumor board programs — must maintain the availability and performance standards that secretory carcinoma's ETV6::NTRK3 fusion-driven molecular diagnosis, TRK inhibitor eligibility, and high-grade transformation surveillance demand. This guide explains why secretory carcinoma tech platforms need dedicated monitoring, what to monitor, and how to build a monitoring strategy matched to the ETV6::NTRK3 molecular confirmation, parotidectomy planning, NTRK inhibitor therapy, and high-grade transformation management of modern secretory carcinoma care.
Why Secretory Carcinoma Tech Platforms Require Specialized Monitoring Attention
Secretory carcinoma management is defined by four platform-dependent complexities: the surgical pathology platform providing ETV6::NTRK3 fusion confirmation, acinic cell carcinoma exclusion, and high-grade transformation recognition that determine prognosis and systemic therapy eligibility; the head and neck surgery platform supporting parotidectomy with facial nerve preservation and grade-dependent neck dissection; the adjuvant radiation oncology platform for adverse-feature and high-grade transformation cases; and the molecular profiling and NTRK inhibitor oncology platform for recurrent or metastatic disease.
Surgical pathology platforms drive ETV6::NTRK3 molecular confirmation, high-grade transformation recognition, and acinic cell carcinoma exclusion that determine eligibility for TRK inhibitor therapy. ETV6::NTRK3 fusion confirmation by FISH, RT-PCR, or RNA sequencing is the definitive molecular step that both confirms the secretory carcinoma diagnosis and establishes TRK inhibitor eligibility — making the molecular pathology platform a direct therapeutic gating step. High-grade transformation recognition (increased mitotic activity, comedonecrosis, nuclear pleomorphism, solid growth) is the histologic determination that escalates systemic therapy consideration from observation to active NTRK inhibitor or platinum-based chemotherapy evaluation. Monitor surgical pathology platforms during diagnostic hours.
Head and neck surgery platforms support parotidectomy with facial nerve preservation and high-grade transformation-dependent neck dissection. The 20–30% cervical nodal metastasis rate at presentation in secretory carcinoma — significantly higher than in acinic cell carcinoma, the principal clinical differential — means that neck management (elective neck dissection, sentinel lymph node biopsy, or CT/MRI nodal staging) is a routine part of surgical planning, not the exceptional one it is in truly low-metastatic-rate salivary gland tumors. High-grade transformation with T3–T4 disease or clinical nodal disease requires comprehensive neck dissection and total parotidectomy. Monitor head and neck surgery platforms during operative and perioperative hours.
Adjuvant IMRT platforms serve adverse-feature secretory carcinoma with perineural invasion, nodal disease, or high-grade transformation. Adjuvant radiotherapy for secretory carcinoma follows the same adverse-feature indications as for other intermediate-grade salivary gland carcinomas — close or positive margins, perineural invasion, nodal disease with extranodal extension, T3–T4 stage, high-grade transformation — with IMRT to the primary bed and regional nodes. Monitor radiation oncology platforms during treatment delivery hours.
NTRK inhibitor platforms are the definitive systemic therapy pathway for recurrent or metastatic secretory carcinoma. Larotrectinib and entrectinib — FDA-approved pan-NTRK inhibitors — achieve objective response rates of 70–80%+ in TRK fusion-positive tumors including secretory carcinoma, making ETV6::NTRK3 fusion confirmation in the surgical pathology and molecular profiling platforms a direct gatekeeper for the most effective systemic therapy option for recurrent disease. Monitor NTRK inhibitor administration platforms during clinical hours.
What to Monitor on a Secretory Carcinoma Tech Platform
Surgical Pathology Platforms
Monitor secretory carcinoma surgical pathology records (growth pattern documentation — microcystic, tubular, papillary-cystic, solid percentage; secretory vacuole and PAS-diastase positive intracytoplasmic vacuole identification; colloid-like intraluminal secretory material; high-grade transformation features — mitotic count >4/10 HPF, comedonecrosis, solid sheet growth, nuclear pleomorphism; T-stage — T1: ≤2 cm; T2: >2 cm, ≤4 cm; T3: >4 cm or extraparenchymal extension; T4a: skin, mandible, ear canal, facial nerve; margin status — millimeters from inked margin; perineural invasion — named nerve branch documentation; lymphovascular invasion; lymph node status — number positive, extranodal extension documentation), ETV6 break-apart FISH records (ETV6 rearrangement — split red and green signals confirming ETV6 disruption), dual-fusion ETV6/NTRK3 FISH records, RNA sequencing or RT-PCR records for ETV6::NTRK3 fusion transcript confirmation, IHC records (S100 — diffuse strong positive; mammaglobin — diffuse positive [highly specific for secretory carcinoma among salivary tumors]; GATA3 — positive; SOX10 — positive; DOG1 — negative [acinic cell carcinoma exclusion]; NR4A3 — negative [acinic cell carcinoma exclusion]; NTRK IHC pan-TRK — positive as screening; PAS-diastase positive secretory vacuoles [acinic cell carcinoma: zymogen granules DOG1+ NR4A3+ NR4A3-rearranged vs. secretory carcinoma: S100+ mammaglobin+ ETV6-rearranged]), and comprehensive molecular profiling records for high-grade transformation cases. Alert immediately — surgical pathology platform failures when the medical oncologist awaiting ETV6::NTRK3 FISH results for a patient with recurrent parotid secretory carcinoma cannot access the molecular confirmation required for larotrectinib prescription.
Head and Neck Surgery Platforms
Monitor parotidectomy operative records (superficial vs. total parotidectomy decision and documentation; deep lobe involvement and deep lobe resection; continuous intraoperative facial nerve monitoring records — NIM EMG; facial nerve branch stimulation thresholds before and after tumor dissection; postoperative House-Brackmann grade at discharge), neck dissection operative records (ipsilateral selective neck dissection levels I–III for N0 T2+ disease and low-grade secretory carcinoma; comprehensive levels I–V for clinical nodal disease and high-grade transformation; lymph node yield; extranodal extension documentation), and re-excision records for positive margin cases. Alert immediately — head and neck surgery platform failures prevent the postoperative team from accessing the parotidectomy operative records documenting the extent of facial nerve dissection (all five branches traced and preserved vs. branch sacrifice for direct tumor involvement) and the neck dissection nodal findings needed by the radiation oncology team for adjuvant IMRT field planning.
Adjuvant Radiation Oncology Platforms
Monitor IMRT simulation and treatment planning records for adverse-feature secretory carcinoma (CT simulation with MRI parotid fusion; GTV delineation — primary tumor bed, positive nodes, extranodal extension zones; CTV high-risk — parotid bed, involved nodal basins; CTV intermediate-risk — elective nodal coverage for T2+ and high-grade transformation; dose prescription — 60–66 Gy/30–33 fx; OAR constraints — contralateral parotid mean <24 Gy; bilateral cochleae mean <20 Gy; spinal cord <45 Gy; brainstem <54 Gy; mandible D2% <70 Gy), and daily IMRT fraction delivery records including CBCT image guidance, beam delivery MU logs, and ongoing toxicity monitoring (mucositis, xerostomia, dermatitis, dysphagia). Alert immediately — adjuvant radiation oncology platform failures during IMRT prevent the radiation therapist from accessing prior fraction records and CBCT image guidance verification before proceeding with the current fraction.
NTRK Inhibitor Systemic Therapy Platforms
Monitor NTRK inhibitor administration records for recurrent or metastatic secretory carcinoma (larotrectinib 100 mg twice daily — oral; entrectinib 600 mg once daily — oral; dose reduction records — larotrectinib: 75 mg BID → 50 mg BID for Grade 3+ toxicity; entrectinib: 400 mg daily for Grade 3+ toxicity; toxicity monitoring — neurotoxicity [dizziness, cognitive effects, ataxia — both agents], hepatotoxicity [LFT monitoring], QTc prolongation [entrectinib]), response assessment imaging records (CT chest/abdomen/pelvis or site-specific MRI every 8–12 weeks; RECIST 1.1 response criteria), and records for acquired resistance management (NTRK kinase domain resistance mutations — G595R, G667C — detected on liquid biopsy or repeat tumor biopsy — next-generation TRK inhibitors selitrectinib, repotrectinib for resistance mutations). Alert immediately — NTRK inhibitor platform failures when a patient with metastatic ETV6::NTRK3-positive secretory carcinoma on larotrectinib requires urgent access to prior dose reduction records documenting a Grade 2 dizziness-related dose reduction at cycle 2.
Molecular Profiling Platforms
Monitor ETV6 break-apart FISH records and dual-fusion ETV6/NTRK3 FISH records, RNA fusion sequencing records (ETV6::NTRK3 transcript confirmation; alternative ETV6 fusion partner detection; alternative NTRK3 fusion partner detection for ETV6-wild-type cases), pan-TRK IHC records (NTRK IHC cytoplasmic/nuclear positivity as screening), comprehensive NGS records for high-grade transformation cases (TP53, PIK3CA, CDKN2A, TMB, MSI-H, PD-L1 TPS), and liquid biopsy records for acquired TRK inhibitor resistance mutation detection (NTRK3 G595R, G667C, F617L on circulating tumor DNA). Alert immediately — molecular profiling platform failures prevent the medical oncologist from accessing ETV6::NTRK3 fusion confirmation results needed to initiate larotrectinib for progressive metastatic secretory carcinoma.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. Secretory carcinoma programs coordinate across surgical pathology (ETV6::NTRK3 FISH and RNA sequencing, mammaglobin/S100/GATA3 IHC, acinic cell carcinoma exclusion), imaging (MRI parotid, CT neck), head and neck surgery (parotidectomy with facial nerve monitoring, neck dissection), radiation oncology (adjuvant IMRT), medical oncology (larotrectinib, entrectinib, neurotoxicity monitoring), molecular oncology (liquid biopsy for resistance mutations), and multidisciplinary tumor board.
SSL Certificates
Monitor SSL certificate expiry across all patient portals, surgical pathology reporting systems, head and neck surgery operative platforms, radiation therapy delivery systems, NTRK inhibitor administration platforms, and molecular profiling platforms. Certificate errors disrupt ETV6::NTRK3 FISH result access, NTRK inhibitor administration record retrieval, and tumor board platform availability.
HIPAA and Oncology Data Privacy Considerations
Secretory carcinoma technology platforms handle sensitive PHI including ETV6::NTRK3 fusion results (with TRK inhibitor eligibility implications for recurrent or metastatic disease), high-grade transformation documentation (shifting prognosis and escalating systemic therapy indication), NTRK inhibitor neurotoxicity records (cognitive and neurologic adverse effects with workplace and driving safety implications), parotidectomy and facial nerve dissection records, and acquired resistance mutation records from liquid biopsy (circulating tumor DNA results with downstream treatment eligibility and prognosis implications).
Alerting Strategy for Secretory Carcinoma Tech Platforms
Immediate alerting during surgical pathology reporting: ETV6 FISH, RNA fusion sequencing, mammaglobin/S100/GATA3 IHC, acinic cell carcinoma exclusion, and high-grade transformation platforms — ETV6::NTRK3 confirmation determines TRK inhibitor eligibility.
Immediate alerting during parotidectomy and neck dissection: Head and neck surgery operative platforms with facial nerve monitoring records and neck dissection nodal basin documentation for adjuvant IMRT planning.
Immediate alerting during adjuvant IMRT delivery: Radiation therapy delivery platforms with daily CBCT image guidance and adverse-feature field verification.
Immediate alerting during NTRK inhibitor therapy: Larotrectinib and entrectinib administration platforms with neurotoxicity, hepatotoxicity, and QTc monitoring records.
Immediate alerting during molecular profiling: ETV6 FISH, RNA fusion sequencing, pan-TRK IHC, and liquid biopsy resistance mutation platforms.
Sustained-failure alert (10–15 minutes): Facial nerve rehabilitation, speech-language pathology, long-term surveillance, and multidisciplinary tumor board platforms.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms secretory carcinoma platform availability from the geographies where high-volume parotid oncology programs with NTRK fusion-positive tumor expertise and TRK inhibitor prescribing experience operate.
Status Page for Secretory Carcinoma Care Team Communication
A real-time status page gives surgical pathologists confirming ETV6::NTRK3 fusion and performing acinic cell carcinoma exclusion, head and neck surgeons accessing parotidectomy operative and facial nerve monitoring records, radiation oncologists verifying adjuvant IMRT delivery, medical oncologists reviewing ETV6::NTRK3 fusion confirmation and NTRK inhibitor administration records, and multidisciplinary tumor board members coordinating TRK inhibitor eligibility and high-grade transformation management immediate platform visibility without requiring IT support contact.
Include the status page URL in secretory carcinoma pathology downtime procedures, head and neck surgery operative downtime protocols, adjuvant IMRT delivery downtime procedures, and NTRK inhibitor administration downtime protocols.
Vigilmon Setup for Secretory Carcinoma Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Surgical pathology platform / ETV6 FISH, mammaglobin IHC, high-grade transformation | 1 min | Slack + PagerDuty (diagnostic hours) | | Head and neck surgery platform / parotidectomy, facial nerve monitoring, neck dissection | 1 min | Slack + PagerDuty (operative hours) | | Adjuvant IMRT platform / adverse-feature secretory carcinoma delivery and CBCT | 1 min | Slack + PagerDuty (treatment hours) | | Larotrectinib platform / NTRK inhibitor for recurrent/metastatic disease | 1 min | Slack + PagerDuty (clinical hours) | | Entrectinib platform / second TRK inhibitor option | 1 min | Slack + PagerDuty (clinical hours) | | Next-generation TRK inhibitor platform / selitrectinib, repotrectinib for resistance | 1 min | Slack + PagerDuty (clinical hours) | | Molecular profiling platform / ETV6 FISH, RNA sequencing, pan-TRK IHC, liquid biopsy | 1 min | Slack + PagerDuty (diagnostic hours) | | MRI/CT staging platform / parotid extent, nodal staging | 1 min | Slack + PagerDuty (diagnostic hours) | | Facial nerve rehabilitation platform / House-Brackmann serial assessment | 2 min | Slack (clinical hours) | | Speech-language pathology platform / xerostomia, dysphagia post-RT | 2 min | Slack (clinical hours) | | Long-term surveillance platform / recurrence and metastasis monitoring | 2 min | Slack (business hours) | | Multidisciplinary head and neck tumor board | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure surgical pathology platforms with immediate alerting — ETV6::NTRK3 FISH confirmation, mammaglobin and S100 IHC, acinic cell carcinoma exclusion (DOG1/NR4A3 negativity), and high-grade transformation recognition determine TRK inhibitor eligibility and prognosis
- Add head and neck surgery platforms with immediate alerting — facial nerve monitoring records and neck dissection nodal findings are critical inputs for postoperative care and adjuvant IMRT planning
- Configure adjuvant IMRT platforms with immediate alerting for adverse-feature cases including daily CBCT image guidance verification
- Add NTRK inhibitor platforms (larotrectinib, entrectinib) for recurrent or metastatic disease with ETV6::NTRK3 fusion confirmation — the most directly actionable systemic therapy pathway in salivary gland oncology
- Configure next-generation TRK inhibitor platforms (selitrectinib, repotrectinib) for acquired kinase domain resistance mutations
- Add molecular profiling platforms — ETV6 FISH, RNA fusion sequencing, pan-TRK IHC, liquid biopsy for resistance mutations
- Enable SSL certificate monitoring across all clinical, pathology, operative, RT delivery, molecular, and tumor board domains
Conclusion
Secretory carcinoma technology platforms are embedded in clinical decisions where surgical pathology platform availability for ETV6::NTRK3 molecular confirmation and acinic cell carcinoma exclusion — where the surgical pathologist must recognize the secretory carcinoma morphology (microcystic spaces lined by cells with abundant pale vacuolated cytoplasm containing eosinophilic secretory material, tubular structures with colloid-like luminal secretions, PAS-diastase positive intracytoplasmic vacuoles, and optionally papillary-cystic and solid patterns — a morphology that can closely mimic acinic cell carcinoma's microcystic and papillary-cystic patterns at low magnification, but where immunohistochemistry separates the two definitively: secretory carcinoma is S100 diffuse positive, mammaglobin diffuse positive, GATA3 positive, DOG1 negative, and NR4A3 negative — while acinic cell carcinoma is DOG1 positive, NR4A3 positive or NR4A3-rearranged, and mammaglobin negative), confirm the ETV6::NTRK3 fusion by break-apart ETV6 FISH or dual-fusion ETV6/NTRK3 FISH (the molecular confirmation that simultaneously establishes the diagnosis, documents the TRK fusion required for larotrectinib or entrectinib eligibility, and excludes the MYB::NFIB fusion of adenoid cystic carcinoma and the NR4A3 rearrangement of acinic cell carcinoma), and identify high-grade transformation features (increased mitotic activity exceeding 4 per 10 high-power fields, comedonecrosis within the primary tumor, solid sheet growth replacing the microcystic and tubular architecture, and nuclear pleomorphism replacing the characteristic bland cytomorphology of low-grade secretory carcinoma — features whose recognition is critical because high-grade transformation associates with lymph node metastasis in approximately 60–70% of cases [vs. 20–30% for low-grade disease], distant metastasis, and substantially reduced 5-year disease-specific survival, and whose recognition directs the surgeon to comprehensive neck dissection and the medical oncologist to early NTRK inhibitor initiation for residual or recurrent disease rather than expectant observation) — before the head and neck surgeon can complete the neck dissection planning (low-grade T2 N0: elective ipsilateral levels I–III selective neck dissection; high-grade transformation N0: comprehensive modified radical neck dissection levels I–V; clinical nodal disease: comprehensive modified radical neck dissection with contralateral elective coverage for bilateral disease), before the radiation oncologist can design the adjuvant IMRT field (perineural invasion documentation and nodal basin mapping from the neck dissection pathology together determine whether the field encompasses only the parotid bed or additionally covers the regional nodal basins and extended perineural field), and before the medical oncologist can initiate larotrectinib or entrectinib for recurrent or metastatic disease (where ETV6::NTRK3 fusion confirmation from the original tumor's FISH results — retrieved from the surgical pathology platform — is the eligibility document that the oncologist must access before prescription approval) — cannot be interrupted by platform outage when the ETV6::NTRK3 molecular result from the surgical pathology platform is simultaneously the diagnostic confirmation, the TRK inhibitor eligibility document, and the molecular distinction from acinic cell carcinoma that determines the entire treatment pathway; where head and neck surgery platform availability after parotidectomy enables the oncology team to access facial nerve monitoring records that document whether facial nerve function was preserved (a critical rehabilitation and quality-of-life baseline) and neck dissection records that specify whether extranodal extension was present (an adverse feature that triggers adjuvant IMRT regional nodal coverage and an independent predictor of distant metastasis that elevates NTRK inhibitor consideration); and where NTRK inhibitor platform availability during ongoing larotrectinib or entrectinib therapy confirms that dose modification records, neurotoxicity monitoring (dizziness, cognitive effects, ataxia are the most common NTRK inhibitor class toxicities and can affect driving safety and work capacity — requiring documented assessment and dose modification as per the prescribing label), and response assessment imaging records are accessible throughout the treatment course for the secretory carcinoma patient with multiple pulmonary metastases on ongoing oral TRK inhibitor therapy.
Uptime monitoring gives secretory carcinoma tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to surgical pathology programs confirming ETV6::NTRK3 fusion by FISH and RNA sequencing, performing mammaglobin and S100 IHC for secretory carcinoma diagnosis, and identifying high-grade transformation that escalates systemic therapy indication, head and neck surgery programs performing superficial and total parotidectomy with continuous facial nerve monitoring and variant-appropriate neck dissection, radiation oncology programs delivering adjuvant IMRT for adverse-feature and high-grade transformation secretory carcinoma with comprehensive regional nodal coverage, medical oncology programs managing larotrectinib and entrectinib with neurotoxicity and hepatotoxicity monitoring and NTRK kinase domain resistance mutation surveillance by liquid biopsy, molecular oncology programs performing ETV6 FISH, RNA fusion sequencing, pan-TRK IHC, and comprehensive NGS for high-grade transformation, long-term surveillance programs monitoring for late recurrence (secretory carcinoma has a known pattern of late local and regional recurrence requiring multi-year follow-up), and compliance auditors that platform operational reliability matches the ETV6::NTRK3 molecular confirmation precision, acinic cell carcinoma exclusion accuracy, high-grade transformation surveillance, TRK inhibitor administration record integrity, and extended follow-up continuity that modern secretory carcinoma of the salivary gland care demands.
Start monitoring your secretory carcinoma salivary gland care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #secretorycarcinoma #MASC #mammaryanaloguesecretorycarcinoma #ETV6 #NTRK3 #TRKfusion #larotrectinib #entrectinib #salivaryglandcancer #parotidcancer #acinccellcarcinoma #mammaglobin #S100 #GATA3 #headandneckcancer #parotidectomy #facialnerve #IMRT #adjuvantradiotherapy #NTRKinhibitor #highgradetransformation #HIPAA #cancertech #healthtech #digitalhealth #uptime #sre